Compare Novartis AG (NVS) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs RLX Technology Inc — how do they compare? Novartis AG trades at $143.34 (market cap $268.57B), while RLX Technology Inc trades at $1.73 (market cap $2.10B). The key difference: Novartis AG is far larger — about 127.9× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and RLX Technology Inc for 34 Days on average.
| NVS | RLX | |
|---|---|---|
Market Cap | $268.57B | $2.10B |
Volume | 1,532,573 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $2.57 |
52-Week Low | $121.80 | $1.68 |
Typical Hold Time | 82 Days | 34 Days |
Enterprise Value | $309.89B | $832.26M |
Dividend Yield | 3.31% | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
RLX Technology trades at $1.73, near its 52-week low of $1.67, with bearish technical signals from moving averages. The company reported strong 2025 fundamentals with $921.87M net income and 21.87% net margin, though recent quarters show earnings misses. International expansion drives growth, with 70% of revenue now from overseas markets following European acquisitions.
The stock presents a value opportunity with discounted valuation multiples (P/E 15.46, P/B 0.91) but faces headwinds from recent earnings underperformance and bearish technical momentum. Key risks include margin compression and regulatory uncertainty in the e-vapor industry, while analyst sentiment remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
